Quarterly report · Q3
3353.TEDINET S100PYK8
Period2022-03-01 → 2022-11-30
Filed2023-01-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥25.4bn | 2022-03-01 → 2022-11-30 | Cons. | Net sales |
| Revenue | ¥33.6bn | 2021-03-01 → 2022-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥25.2bn | 2021-03-01 → 2021-11-30 | Cons. | Net sales |
| Operating income | ¥706m | 2022-03-01 → 2022-11-30 | Cons. | Operating income |
| Operating income | ¥1.0bn | 2021-03-01 → 2021-11-30 | Cons. | Operating income |
| Ordinary income | ¥888m | 2022-03-01 → 2022-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.4bn | 2021-03-01 → 2022-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2021-03-01 → 2021-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥998m | 2022-03-01 → 2022-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.2bn | 2021-03-01 → 2021-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥597m | 2022-03-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥852m | 2021-03-01 → 2022-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥670m | 2021-03-01 → 2021-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥623m | 2022-03-01 → 2022-11-30 | Cons. | Profit loss |
| Net income | ¥694m | 2021-03-01 → 2021-11-30 | Cons. | Profit loss |
| Total assets | ¥28.0bn | at 2022-11-30 | Cons. | Assets |
| Total assets | ¥29.1bn | at 2022-02-28 | Cons. | Assets |
| Total assets | ¥29.6bn | at 2021-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥15.6bn | at 2022-11-30 | Cons. | Liabilities |
| Total liabilities | ¥17.2bn | at 2022-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥12.4bn | at 2022-11-30 | Cons. | Net assets |
| Net assets / equity | ¥11.9bn | at 2022-02-28 | Cons. | Net assets |
| Net assets / equity | ¥11.7bn | at 2021-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.6bn | at 2022-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥8.0bn | at 2022-02-28 | Cons. | Cash and deposits |
| EPS (basic) | ¥159 | 2022-03-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.34 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥226.92 | 2021-03-01 → 2022-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥178.38 | 2021-03-01 → 2021-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.15 | 2021-09-01 → 2021-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 42.3% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.1% | at 2022-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.7% | at 2021-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-03-01 → 2022-11-30 | −¥744m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-03-01 → 2022-11-30 | −¥744m |
| Reconciling Itemsreconciling | segment profit | 2022-03-01 → 2022-11-30 | −¥557m |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥17.3bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥17.3bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥1.1bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥5.8bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥450,000 |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥35m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥2.9bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥2.2bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥742m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥29m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥142m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥140m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥1m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥92m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-03-01 → 2022-11-30 | ¥26.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-03-01 → 2022-11-30 | ¥25.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥744m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-03-01 → 2022-11-30 | ¥1.3bn |
| Reconciling Itemsreconciling | revenue | 2021-03-01 → 2021-11-30 | −¥808m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-03-01 → 2021-11-30 | −¥808m |
| Reconciling Itemsreconciling | segment profit | 2021-03-01 → 2021-11-30 | −¥518m |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2021-03-01 → 2021-11-30 | ¥17.0bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2021-03-01 → 2021-11-30 | ¥17.0bn |
| jpcrp040300-q3r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2021-03-01 → 2021-11-30 | ¥1.1bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue | 2021-03-01 → 2021-11-30 | ¥5.9bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue external | 2021-03-01 → 2021-11-30 | ¥5.9bn |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | revenue intersegment | 2021-03-01 → 2021-11-30 | ¥450,000 |
| jpcrp040300-q3r_E03443-000Health Carereportable segment | segment profit | 2021-03-01 → 2021-11-30 | ¥225m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue | 2021-03-01 → 2021-11-30 | ¥2.9bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2021-03-01 → 2021-11-30 | ¥2.1bn |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2021-03-01 → 2021-11-30 | ¥806m |
| jpcrp040300-q3r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2021-03-01 → 2021-11-30 | ¥72m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue | 2021-03-01 → 2021-11-30 | ¥175m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue external | 2021-03-01 → 2021-11-30 | ¥174m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | revenue intersegment | 2021-03-01 → 2021-11-30 | ¥1m |
| jpcrp040300-q3r_E03443-000Real Estatereportable segment | segment profit | 2021-03-01 → 2021-11-30 | ¥98m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-03-01 → 2021-11-30 | ¥26.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-03-01 → 2021-11-30 | ¥25.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-03-01 → 2021-11-30 | ¥808m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-03-01 → 2021-11-30 | ¥1.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 366
| Item | Context | Value | Unit |
|---|---|---|---|
| Current portion of long term loans payable | Prior1YearInstant | 3562395000 | JPY |
| Current portion of long term loans payable | CurrentQuarterInstant | 3132819000 | JPY |
| Income taxes payable | Prior1YearInstant | 279828000 | JPY |
| Income taxes payable | CurrentQuarterInstant | 151218000 | JPY |
| Provision for bonuses | Prior1YearInstant | 226908000 | JPY |
| Provision for bonuses | CurrentQuarterInstant | 15142000 | JPY |
| Other cl | Prior1YearInstant | 695487000 | JPY |
| Other cl | CurrentQuarterInstant | 1257877000 | JPY |
| Current liabilities | Prior1YearInstant | 8416097000 | JPY |
| Current liabilities | CurrentQuarterInstant | 8239955000 | JPY |
| Long term loans payable | Prior1YearInstant | 7372883000 | JPY |
| Long term loans payable | CurrentQuarterInstant | 6002567000 | JPY |
| Lease obligations ncl | Prior1YearInstant | 207131000 | JPY |
| Lease obligations ncl | CurrentQuarterInstant | 199399000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 761406000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 788010000 | JPY |
| Other ncl | Prior1YearInstant | 408878000 | JPY |
| Other ncl | CurrentQuarterInstant | 352901000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 8750301000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 7342879000 | JPY |
| Liabilities | Prior1YearInstant | 17166398000 | JPY |
| Liabilities | CurrentQuarterInstant | 15582834000 | JPY |
| Capital stock | Prior1YearInstant | 917000000 | JPY |
| Capital stock | CurrentQuarterInstant | 917000000 | JPY |
| Capital surplus | Prior1YearInstant | 1080381000 | JPY |
| Capital surplus | CurrentQuarterInstant | 1081272000 | JPY |
| Retained earnings | Prior1YearInstant | 9948627000 | JPY |
| Retained earnings | CurrentQuarterInstant | 10395669000 | JPY |
| Treasury stock | Prior1YearInstant | -541555000 | JPY |
| Treasury stock | CurrentQuarterInstant | -539830000 | JPY |
| Shareholders equity | Prior1YearInstant | 11404452000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 11854110000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | -20093000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | -31428000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | -1295000 | JPY |
| Remeasurements of defined benefit plans | CurrentQuarterInstant | -323000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | -21389000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | -31752000 | JPY |
| Non controlling interests | Prior1YearInstant | 544795000 | JPY |
| Non controlling interests | CurrentQuarterInstant | 570230000 | JPY |
| Net assets | Prior1YearInstant | 11927858000 | JPY |
| Net assets | CurrentQuarterInstant | 12392588000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 29094256000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 27975422000 | JPY |
| Net sales | Prior1YTDDuration | 25211390000 | JPY |
| Net sales | CurrentYTDDuration | 25427609000 | JPY |
| Cost of sales | Prior1YTDDuration | 22467320000 | JPY |
| Cost of sales | CurrentYTDDuration | 23002205000 | JPY |
| Gross profit | Prior1YTDDuration | 2744069000 | JPY |
| Gross profit | CurrentYTDDuration | 2425403000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |